@sexyageing's HRT explainer is mostly on target

What did @sexyageing actually say?

The creator gave a general explainer on hormone replacement therapy for menopause, describing it as a way to "bring some of those hormone levels back up and relieve the symptoms of menopause." She covered the estrogen-progesterone split, noted that blood tests aren't always required for diagnosis in women over 45, and mentioned her own Mirena IUD as a progesterone delivery method. She also said there's a "general consensus that you can take HRT for up to five years" while acknowledging some women stay on it far longer. The disclaimer that she's not a doctor but works with them was included upfront.

The video is targeted at people new to menopause, and for that audience it functions as a reasonable starting map. But a few specific claims deserve closer scrutiny, and one framing issue could genuinely mislead viewers about duration of treatment.

Does the science back this up?

Mostly, yes, with some important caveats. The core claim that estrogen, progesterone, and testosterone decline during perimenopause and menopause is well-established. The clinical rationale for combined versus estrogen-only HRT based on uterine status is accurate and consistent with current guidelines from NICE and the Menopause Society.

The claim that you "genuinely don't need a blood test" for women over 45 is supported by UK clinical guidance. NICE guideline NG23 (2015, updated 2019) states that menopause can be diagnosed clinically in women over 45 with relevant symptoms, without hormone testing. Blood tests are recommended for women under 45 because FSH levels are more diagnostically useful when premature ovarian insufficiency is suspected. So she got that right, even if it surprises people.

The estrogen delivery forms she listed, including tablets, patches, gels, implants, and sprays, are all legitimate. Transdermal forms in particular are associated with lower venous thromboembolism risk compared to oral estrogen. Vinogradova et al. (2019, BMJ) confirmed this difference in a large UK cohort study, which is a meaningful clinical detail she didn't mention but didn't contradict either.

What did they get wrong (or right)?

The "up to five years" framing is where this video stumbles. That five-year figure is outdated as a hard cap. It originates partly from the Women's Health Initiative (Rossouw et al., 2002, JAMA), which found elevated breast cancer risk in women taking combined oral HRT, but that study used oral conjugated equine estrogen with medroxyprogesterone acetate, not the transdermal formulations most commonly prescribed today.

The British Menopause Society and NICE both now state that there is no arbitrary duration limit on HRT for most women. Risk-benefit assessment should be individualised and reviewed annually. The Collaborative Group on Hormonal Factors in Breast Cancer (2019, Lancet) did find that combined HRT carries a small increased breast cancer risk that persists with duration of use, but this needs to be weighed against cardiovascular, bone, and quality-of-life benefits. Saying "we'll see about that" about the five-year guidance is actually closer to the current clinical thinking than the five-year cap itself.

On testosterone: she mentioned it as one of the declining sex hormones but didn't explain that testosterone is not included in most standard HRT prescriptions and requires separate prescribing. That's a gap worth flagging for a new audience.

What should you actually know?

HRT is not a monolith. The risk profile of combined oral HRT, combined transdermal HRT, and estrogen-only HRT differs meaningfully, and those differences matter for individual decision-making. The five-year figure the creator cites is not a clinical consensus in 2024. Current guidance from NICE and the British Menopause Society supports individualised, ongoing risk-benefit review rather than a fixed cutoff.

The Mirena IUD as a progesterone component of HRT is clinically recognised and used in practice, though it's worth noting this is an off-label use in some jurisdictions. The creator's personal account of symptom relief is consistent with trial data: the WISDOM trial and multiple observational studies show symptom benefit for a significant proportion of women.

• Blood test thresholds for menopause diagnosis vary by age. Don't assume one rule applies to everyone.
• Transdermal estrogen carries lower clot risk than oral tablets. This matters if you have cardiovascular risk factors.
• Testosterone is a separate conversation from standard HRT and requires its own clinical assessment.
• Duration of HRT use should be reviewed annually with your prescriber, not based on a fixed five-year rule.